Homepage
Open in app
Sign inGet started

The Biotech Social Contract

These articles clearly frame the biotech social contract, explore how it’s really being broken and how it’s not, and propose realistic improvements to encourage affordable healthcare innovation for ourselves and future generations. Guest/co-authors with ideas welcome.

America’s Social Contract with the Biopharmaceutical Industry

America’s Social Contract with the Biopharmaceutical Industry

Peter Kolchinsky, Ph.D.
Go to the profile of Peter Kolchinsky
Peter Kolchinsky
Dec 27, 2017
What happens when a drug won’t go generic?

What happens when a drug won’t go generic?

Peter Kolchinsky, Ph.D.
Go to the profile of Peter Kolchinsky
Peter Kolchinsky
Dec 27, 2017
Protecting Off-Patent Sole-source Drugs from Price-Jacking

Protecting Off-Patent Sole-source Drugs from Price-Jacking

Peter Kolchinsky, Ph.D.
Go to the profile of Peter Kolchinsky
Peter Kolchinsky
Dec 27, 2017
Why wait for generics? In praise of me-too drugs

Why wait for generics? In praise of me-too drugs

Peter Kolchinsky, Ph.D
Go to the profile of Peter Kolchinsky
Peter Kolchinsky
Mar 24, 2018
False Heroes — How PBMs Add Insult to the Injury of Insurance Cost-Sharing

False Heroes — How PBMs Add Insult to the Injury of Insurance Cost-Sharing

Peter Kolchinsky, Ph.D.
Go to the profile of Peter Kolchinsky
Peter Kolchinsky
Mar 24, 2018
Op-Ed
Let’s Throw a Patent-Burning Party

Let’s Throw a Patent-Burning Party

When a drug goes generic, it’s as if society has paid off a mortgage
Go to the profile of Peter Kolchinsky
Peter Kolchinsky
Oct 31, 2018
Latest
The Favors They Do Us: Charging Less in Other Countries Makes Drugs More Affordable in America

The Favors They Do Us: Charging Less in Other Countries Makes Drugs More Affordable in America

Peter Kolchinsky, Ph.D.
Go to the profile of Peter Kolchinsky
Peter Kolchinsky
Oct 4, 2018
Hard Negotiating Tactics: Compulsory Licensing and Willingness to Deny

Hard Negotiating Tactics: Compulsory Licensing and Willingness to Deny

Peter Kolchinsky, Ph.D.
Go to the profile of Peter Kolchinsky
Peter Kolchinsky
Oct 4, 2018
Unintended Consequences of “Fairness”: Critically examining the idea of the US referencing EU…

Unintended Consequences of “Fairness”: Critically examining the idea of the US referencing EU…

Anthony Bower Ph.D. and Peter Kolchinsky, Ph.D.
Go to the profile of Peter Kolchinsky
Peter Kolchinsky
Oct 5, 2018
Direct-to-Consumer (DTC) advertising: misnamed, misunderstood, and underappreciated

Direct-to-Consumer (DTC) advertising: misnamed, misunderstood, and underappreciated

Maligned by doctors and often parodied, appropriately regulated direct-to-consumer drug advertising is a net positive for American…
Go to the profile of Peter Kolchinsky
Peter Kolchinsky
Dec 20, 2018
The strange and special case of epinephrine

The strange and special case of epinephrine

The biotech social contract stipulates that all drugs must go generic. But what if genericization is bad for public health?
Go to the profile of Peter Kolchinsky
Peter Kolchinsky
Dec 20, 2018
About The Biotech Social ContractLatest StoriesArchiveAbout MediumTermsPrivacy